Q2 Earnings Estimate for IRWD Issued By Zacks Research

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) – Analysts at Zacks Research issued their Q2 2027 EPS estimates for Ironwood Pharmaceuticals in a research note issued on Monday, September 8th. Zacks Research analyst Team expects that the biotechnology company will post earnings per share of $0.01 for the quarter. Zacks Research has a “Hold” rating on the stock. The consensus estimate for Ironwood Pharmaceuticals’ current full-year earnings is $0.10 per share.

Separately, Wall Street Zen upgraded shares of Ironwood Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Saturday, August 9th. One investment analyst has rated the stock with a Buy rating and six have given a Hold rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $4.94.

Ironwood Pharmaceuticals Trading Down 1.8%

NASDAQ:IRWD opened at $1.11 on Tuesday. The stock has a market capitalization of $180.30 million, a price-to-earnings ratio of -22.20 and a beta of 0.33. The firm has a fifty day simple moving average of $0.95 and a two-hundred day simple moving average of $0.98. Ironwood Pharmaceuticals has a 12 month low of $0.53 and a 12 month high of $5.13.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last posted its quarterly earnings results on Thursday, August 7th. The biotechnology company reported $0.14 EPS for the quarter, topping analysts’ consensus estimates of ($0.02) by $0.16. The business had revenue of $85.24 million during the quarter, compared to analysts’ expectations of $62.02 million. Ironwood Pharmaceuticals had a negative net margin of 2.25% and a negative return on equity of 2.46%. Ironwood Pharmaceuticals has set its FY 2025 guidance at EPS.

Institutional Investors Weigh In On Ironwood Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Armistice Capital LLC increased its position in shares of Ironwood Pharmaceuticals by 17.9% during the second quarter. Armistice Capital LLC now owns 16,150,000 shares of the biotechnology company’s stock worth $11,583,000 after acquiring an additional 2,450,000 shares in the last quarter. Acadian Asset Management LLC increased its position in shares of Ironwood Pharmaceuticals by 147.6% during the second quarter. Acadian Asset Management LLC now owns 6,549,687 shares of the biotechnology company’s stock worth $4,685,000 after acquiring an additional 3,904,498 shares in the last quarter. Millennium Management LLC increased its position in shares of Ironwood Pharmaceuticals by 186.6% during the first quarter. Millennium Management LLC now owns 6,359,682 shares of the biotechnology company’s stock worth $9,349,000 after acquiring an additional 4,140,439 shares in the last quarter. AQR Capital Management LLC increased its position in shares of Ironwood Pharmaceuticals by 144.3% during the second quarter. AQR Capital Management LLC now owns 6,165,637 shares of the biotechnology company’s stock worth $4,422,000 after acquiring an additional 3,641,762 shares in the last quarter. Finally, Marshall Wace LLP increased its position in shares of Ironwood Pharmaceuticals by 616.3% during the second quarter. Marshall Wace LLP now owns 3,993,557 shares of the biotechnology company’s stock worth $2,875,000 after acquiring an additional 3,436,036 shares in the last quarter.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.